Literature Archives

Highlights the diagnostic utility and clinical impact of bronchoalveolar lavage in evaluating suspected pneumonia in the ICU.

Highlights ongoing debates regarding the optimal management strategy for malignant central airway obstruction.

Provides broader context on multidisciplinary management of NSCLC that impacts staging and biopsy referrals.

Artificial intelligence significantly enhances procedural safety and diagnostic accuracy, with robotic bronchoscopy systems achieving biopsy success rates up to 98.8 percent. Clinicians should anticipate these tools driving standardized practices and personalized medicine, despite remaining challenges in algorithm validation and data privacy.

For interventional pulmonologists, the study highlights that while bronchoscopy is overwhelmingly the first-choice biopsy modality at 90.1%, clinicians are heavily reliant on clinical gestalt and face significant administrative and resource burdens, prioritizing better nodule tracking tools and more accurate risk assessment models.

Provides high-level context on current and emerging airway disease management relevant to interventional pulmonologists.

Non-invasive triage tools may eventually alter referral patterns for diagnostic bronchoscopy and nodule management.

Highlights ongoing limitations in targeting peripheral pulmonary lesions during screening and bronchoscopy.

Reinforces the evidence and efficacy of combined intrapleural fibrinolytic therapy for complex pleural infections and empyema.

Robotic-assisted bronchoscopy is a viable salvage tool for peripheral tracheobronchial foreign bodies inaccessible to conventional bronchoscopes, as demonstrated by the successful retrieval of a 1.9 cm metallic dental drill from the right lower lobe.

EBUS-TBNA tissue biopsies detected significantly more clinically relevant mutations than blood-based liquid biopsies (39.7% versus 29.6%, yield difference 15.1%, 95% CI 5.5% to 24.2%, P = 0.001). However, since a small percentage of patients had mutations detected in blood only, liquid biopsy remains a complementary tool in clinical practice.

Patients with a high burden of three or more comorbidities achieved comparable functional, physiological, and quality-of-life improvements at 12 months as those with fewer comorbidities, though one-year mortality was 5.4 percent versus zero percent in the lower comorbidity group (P = 0.061). Clinicians should not automatically withhold bronchoscopic lung volume reduction evaluation from severe emphysema patients simply due to multiple comorbid conditions.